top of page

Synergy Biologics News

Check back for exciting news and information about Synergy Biologics. 

synergy banner.jpg

March 2024

Synergy Biologics Awarded Reconstructive Skin Grafting Agreement with Premier, Inc.

Contract Allows for Greater Patient Access for Advanced Regenerative Allografts

Tallahassee, FL – Synergy Biologics, a leading developer in regenerative medical solutions, is thrilled to announce that it has been awarded a national group purchasing agreement for Reconstructive Skin Grafting with Premier, Inc. Effective April 1,2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Synergy Biologics' amnion allografts – surgiGRAFT(TM).

This agreement sets a landmark collaboration to broaden the availability of cutting-edge amnion allografts for patients while simultaneously helping to reduce costs for healthcare providers.

A Leap Forward for Regenerative Medicine

Synergy Biologics' innovative approach to skin healing and regeneration has taken a robust step forward thanks to this strategic collaboration. Synergy Biologics will leverage Premier's extensive network to distribute their amniotic allografts, facilitating an increase in accessibility and affordability of these important medical products.

The surgiGRAFT suite of products includes amniotic tissue derived allografts intended for reconstruction, repair, or replacement of a patient’s tissue. Its orientation neutral, hydrated form allow tissue to conform to the surface or surgical site.  Grafts also come in a dry form for handling properties that allow easy application for open surgical techniques.  Terminally sterilized with up to a 3-year shelf life allows for ambient storage and its fully resorbable properties allow for applications directly over bone, tendon, nerves, and wounds.  SurgiGraft is available in a range of sizes for optimal coverage.

Commitment to Accessibility and Sustainability

"The necessary demand for this efficacious donated tissue has become abundantly clear to support physicians’ clinical need for healing their patients. We are honored to be able to collaborate with Premier and provide our cost-effective option, surgiGRAFT(TM). We look forward to continuing our mission to opening access to all patients for this advanced regenerative biologic,” states Montie Lewing, VP of Clinical Sales of Synergy Biologics.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.

Forward-Looking Initiative

"We believe that this collaboration aligns perfectly with our mission to provide products that not only deliver exceptional clinical benefits but also maintain our commitment to cost-effectiveness," said David Hill, CEO of Synergy Biologics. "Working together with Premier underscores our dedication to making advanced tissue biologics more accessible to all patients."


Synergy Biologics is a vertically integrated biotechnology company focused on the development of a safe, reliable, effective, and affordable suite of products designed to enable the physician to achieve the best possible outcomes for each patient. Through our ability to control each and every aspect of tissue transplant, from recovery and screening through processing and distribution, we are committed to providing the very best quality to our customers.


For more information about Synergy Biologics, please click here.

bottom of page